dc.contributor.author | Panopoulou, A | |
dc.contributor.author | Easdale, S | |
dc.contributor.author | Ethell, M | |
dc.contributor.author | Nicholson, E | |
dc.contributor.author | Potter, M | |
dc.contributor.author | Giotas, A | |
dc.contributor.author | Woods, H | |
dc.contributor.author | Thornton, T | |
dc.contributor.author | Pawlyn, C | |
dc.contributor.author | Boyd, KD | |
dc.contributor.author | Kaiser, MF | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2023-02-21T13:21:05Z | |
dc.date.available | 2023-02-21T13:21:05Z | |
dc.date.issued | 2023-02-01 | |
dc.identifier.citation | HemaSphere, 2023, 7 (2), pp. e831 - | |
dc.identifier.issn | 2572-9241 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5692 | |
dc.identifier.eissn | 2572-9241 | |
dc.identifier.eissn | 2572-9241 | |
dc.identifier.doi | 10.1097/HS9.0000000000000831 | |
dc.description.abstract | Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could inform real-world risk-stratified post-ASCT strategies. We investigated the impact of double hit genetics (≥2 adverse markers: t(4;14), t(14;16), t(14;20), gain(1q), del(17p)) on outcome in 139 NDMM patients who underwent SoC ASCT between January 2014 and October 2019 at our center. Double hit genetics were associated with a significantly shortened progression-free survival (hazard ratio [HR] = 4.27, P < 0.001) and overall survival (HR = 4.01, P = 0.03), and characterized most early relapses. Our results support the real-world utility of extended genetic profiling for improved risk prediction in NDMM. | |
dc.format | Electronic-eCollection | |
dc.format.extent | e831 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | |
dc.relation.ispartof | HemaSphere | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-12-19 | |
dc.date.updated | 2023-02-21T11:34:08Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1097/HS9.0000000000000831 | |
rioxxterms.licenseref.startdate | 2023-02-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36751511 | |
pubs.issue | 2 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Myeloma Molecular Therapy | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1097/hs9.0000000000000831 | |
pubs.volume | 7 | |
icr.researchteam | Myeloma Molecular Therapy | |
dc.contributor.icrauthor | Pawlyn, Charlotte | |
dc.contributor.icrauthor | Kaiser, Martin | |
icr.provenance | Deposited by Dr Martin Kaiser on 2023-02-21. Deposit type is initial. No. of files: 1. Files: Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.pdf | |